76 related articles for article (PubMed ID: 21245446)
1. Development of epitope-blocking ELISA for universal detection of antibodies to human H5N1 influenza viruses.
Prabakaran M; Ho HT; Prabhu N; Velumani S; Szyporta M; He F; Chan KP; Chen LM; Matsuoka Y; Donis RO; Kwang J
PLoS One; 2009; 4(2):e4566. PubMed ID: 19238211
[TBL] [Abstract][Full Text] [Related]
2. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.
Friesen RH; Koudstaal W; Koldijk MH; Weverling GJ; Brakenhoff JP; Lenting PJ; Stittelaar KJ; Osterhaus AD; Kompier R; Goudsmit J
PLoS One; 2010 Feb; 5(2):e9106. PubMed ID: 20161706
[TBL] [Abstract][Full Text] [Related]
3. Rapid Generation of Human-Like Neutralizing Monoclonal Antibodies in Urgent Preparedness for Influenza Pandemics and Virulent Infectious Diseases.
Meng W; Pan W; Zhang AJ; Li Z; Wei G; Feng L; Dong Z; Li C; Hu X; Sun C; Luo Q; Yuen KY; Zhong N; Chen L
PLoS One; 2013; 8(6):e66276. PubMed ID: 23824680
[TBL] [Abstract][Full Text] [Related]
4. Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus Transmission in the Guinea Pig Model.
Tan J; Chromikova V; O'Dell G; Sordillo EM; Simon V; van Bakel H; Krammer F; McMahon M
mSphere; 2022 Oct; 7(5):e0092721. PubMed ID: 36069438
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic applications of monoclonal antibodies.
Berger M; Shankar V; Vafai A
Am J Med Sci; 2002 Jul; 324(1):14-30. PubMed ID: 12120821
[TBL] [Abstract][Full Text] [Related]
6. [Advances of monoclonal antibodies and analysis of marketed antibody drugs].
Gu G; Fang M
Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1431-1447. PubMed ID: 38783807
[TBL] [Abstract][Full Text] [Related]
7. Scaling-up and production of therapeutic antibodies for preclinical studies.
Feng Y; Dimitrov DS
Methods Mol Biol; 2009; 525():499-508, xiii. PubMed ID: 19252843
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a humanized ST6GAL1 mouse model for influenza research.
Chao L; Feng H; Qian G; Limin L; Ziwei L; Shuangshuang L; Xiaoyan L; Yuechao H; Mengjie Y; Yingze Z; Jun L; Xuancheng L; Shuguang D
Animal Model Exp Med; 2024 Jun; ():. PubMed ID: 38859745
[TBL] [Abstract][Full Text] [Related]
9. Designing stable humanized antibodies.
Hummer AM; Deane CM
Nat Biomed Eng; 2024 Jan; 8(1):3-4. PubMed ID: 38151639
[No Abstract] [Full Text] [Related]
10. Antibody-mediated prevention and treatment of HIV-1 infection.
Gruell H; Klein F
Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
[TBL] [Abstract][Full Text] [Related]
11. A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge.
Du R; Mao Q; Hu Y; Lang S; Sun S; Li K; Gao F; Bian L; Yang C; Cui B; Xu L; Cheng T; Liang Z
Hum Vaccin Immunother; 2019; 15(10):2343-2350. PubMed ID: 30735461
[TBL] [Abstract][Full Text] [Related]
12. Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD).
Mendoza M; Ballesteros A; Qiu Q; Pow Sang L; Shashikumar S; Casares S; Brumeanu TD
Hum Vaccin Immunother; 2018 Feb; 14(2):345-360. PubMed ID: 29135340
[TBL] [Abstract][Full Text] [Related]
13. Passive broad-spectrum influenza immunoprophylaxis.
Berry CM; Penhale WJ; Sangster MY
Influenza Res Treat; 2014; 2014():267594. PubMed ID: 25328697
[TBL] [Abstract][Full Text] [Related]
14. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model.
Li Z; Xu L; He D; Yang L; Liu C; Chen Y; Shih JW; Zhang J; Zhao Q; Cheng T; Xia N
PLoS One; 2014; 9(10):e109391. PubMed ID: 25279734
[TBL] [Abstract][Full Text] [Related]
15. Novel approaches and challenges to treatment of central nervous system viral infections.
Nath A; Tyler KL
Ann Neurol; 2013 Sep; 74(3):412-22. PubMed ID: 23913580
[TBL] [Abstract][Full Text] [Related]
16. Extent of antigenic cross-reactivity among highly pathogenic H5N1 influenza viruses.
Ducatez MF; Cai Z; Peiris M; Guan Y; Ye Z; Wan XF; Webby RJ
J Clin Microbiol; 2011 Oct; 49(10):3531-6. PubMed ID: 21832017
[TBL] [Abstract][Full Text] [Related]
17. Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses.
Zheng Q; Xia L; Wu WL; Zheng Z; Huo Y; Wu J; Liu Y; Yu H; Chen Y; Lau SY; Chen H; Luo W; Xia N
Antimicrob Agents Chemother; 2011 Apr; 55(4):1349-57. PubMed ID: 21245446
[TBL] [Abstract][Full Text] [Related]
18. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.
Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S
J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719
[TBL] [Abstract][Full Text] [Related]
19. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms.
Tan Y; Ng Q; Jia Q; Kwang J; He F
J Virol; 2015 Apr; 89(7):3712-22. PubMed ID: 25609802
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
